Theravance Inc news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

THRX 15.32 +1.06 (7.43%)
price chart
Theravance, Inc. Appoints Michael Faerm as Chief Business Officer
Theravance, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals.
Theravance: On Track To Deliver Rising Dividends
This would be at the lower end of my forecasted range. However, as Theravance receives a higher royalty rate of 15% on the much higher sales of Breo and 6.5% on sales of Anoro, at GBP42m (= ~$65m) the total forecasted royalty income would still reach ...
Theravance Inc (THRX) Announces Quarterly Dividend of $0.25  Dakota Financial News
Biotech Stocks leaving investors heartbroken - Theravance Inc (NASDAQ:THRX ...  Wall Street Observer
Volatile Theravance Inc. Offers Attractive Total Returns Potential (THRX)
Theravance, Inc. is a royalty management company. The South San Francisco, California-headquartered company is primarily focused on maximizing the potential value of the respiratory assets partnered with United Kingdom-based pharmaceutical giant ...
Wall Street Places $14 Price Target on Theravance, Inc. (NASDAQ:THRX)
In looking at the consensus numbers, the sell-side analysts covering the stock have a mean target price of $14 for Theravance, Inc. (NASDAQ:THRX). This number is the mean estimate from the 4 research brokerages that recently issued reports on the firm.
Theravance, Inc. (NASDAQ:THRX) Short Interest Update  OTC Outlook
Shining on Major News: Theravance Inc. (NASDAQ:THRX), Merck & Co. Inc ...  Stock Transcript
Form 4 THERAVANCE INC For: Jul 23 Filed by: Faerm Michael E.
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. Faerm Michael E. (Last), (First), (Middle). 951 GATEWAY BLVD. (Street). SOUTH SAN ...
Theravance, Inc. Price Target Update
Theravance, Inc. (NASDAQ:THRX): The mean short term price target for Theravance, Inc. (NASDAQ:THRX) has been established at $14 per share.
Theravance, Inc. Short Interest Update  OTC Outlook
Theravance Inc (THRX) Discloses Form 4 Insider Selling : James L Tyree Sells ...
Theravance Inc (THRX) Discloses Insider Transaction. James L Tyree , director of Theravance Inc sold 2,438 shares on Jun 2, 2015.
Inside Trading: James Tyree Unloaded 2438 Shares of Theravance Inc (NASDAQ:THRX)
Stock Update - Theravance, Inc. (NASDAQ:THRX)
Theravance, Inc. (NASDAQ:THRX) shares closed the last trading session at 15.62. In the current trading session the stock reached as high as 15.38 and dipped down to 13.86.
Theravance, Inc. (NASDAQ:THRX) Analyst Rating in Focus
Theravance, Inc. (NASDAQ:THRX) shares have been given a 3.26 rating by analysts surveyed by Zacks Investment Research.
Can Theravance, Inc. (NASDAQ:THRX) Keep Up with Analyst Expectations?
Theravance, Inc. (NASDAQ:THRX) reported an earnings surprise of -12.5% when the company last reported earnings for the period ending on 2015-03-31.